Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- Primus Partners and iSPIRIT release a blueprint for India’s DPI to drive the Global South’s SDG progress
- ‘Andhra Pradesh set to lead South Asia in data revolution’: Nara Lokesh
- Web3 to power India’s economic growth, expected to drive 27% of India’s incremental GDP by 2032: Study
- RBI MPC Meeting: Governor Shaktikanta Das has some strong messages for NBFCs
